Picibanil

Names

[ Name ]:
Picibanil

[Synonym ]:
(2S,5R,6R)-3,3-Dimethyl-7-oxo-6-[(phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-, ion(1-), (2S,5R,6R)-

Biological Activity

[Description]:

Picibanil (OK-432) is a streptococcal preparation with potent biological response modifying activities. Picibanil also has anticancer activity. Picibanil can be used for the research of cancers such as lymphangiomas[1][2][3].

[Related Catalog]:

Research Areas >> Cancer

Research Areas >> Infection

Signaling Pathways >> Others >> Others

Research Areas >> Inflammation/Immunology

[In Vitro]

OK-432 诱导多种细胞因子，激活免疫细胞，增强抗癌免疫力[3]。 OK-432 诱导树突状细胞 (DC) 成熟[3]。

[In Vivo]

Picibanil（腹腔注射；1.0 KE/小鼠；2-10 天）增加白细胞介素 1 (IL-1) 和白细胞介素 2 (IL-2) 的产生[2]。 Animal Model: BALB/c mice[2] Dosage: 1.0 KE/mouse Administration: Intraperitoneal; 2-10 day Result: Augmented IL-I production by macrophages and 1L-2 production.

[References]

[1]. Ryoma, Yoshiki et al. Biological effect of OK-432 (picibanil) and possible application to dendritic cell therapy. Anticancer research vol. 24,5C (2004): 3295-301.

[2]. Ichimura, O et al. Augmentation of interleukin 1 and interleukin 2 production by OK-432. International journal of immunopharmacology vol. 7,2 (1985): 263-70.

[3]. Giguère, Chantal M et al. Treatment of lymphangiomas with OK-432 (Picibanil) sclerotherapy: a prospective multi-institutional trial. Archives of otolaryngology--head & neck surgery vol. 128,10 (2002): 1137-44.

Chemical & Physical Properties

[ Boiling Point ]:
663.3±55.0 °C at 760 mmHg

[ Molecular Formula ]:
C₁₆H₁₇N₂O₄S

[ Molecular Weight ]:
333.383

[ Flash Point ]:
355.0±31.5 °C

[ Exact Mass ]:
333.091461

[ LogP ]:
1.67

[ Vapour Pressure ]:
0.0±2.1 mmHg at 25°C

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.